Biomiga Diagnostics will be presenting at EMAS 2012, Athens, Greece, on March 28.

March 6, 2012 - PRLog -- Biomiga Diagnostics, a molecular diagnostics company, announced today that  its abstract―Therapeutic Drug Monitoring (TDM) assays for LH and FSH―will be presented as electronically viewed poster at EMA2012.  Hormone manipulation therapies, such as FSH, used for induction of egg production during In Vitro Fertilization protocol, and long-acting GnRH agonists, used in the treatment of estrogen-dependent forms of breast cancer, as well as prostate cancer, are frequently monitored by quantitation of LH and/or FSH. Traditionally, these hormones are measured by ELISA assays that require blood to be drawn at either a doctor’s office or a diagnostic laboratory. Here, Dr. Vuong Trieu and colleagues describe the development of rapid point-of-care tests for detection of these hormones that are quantitative and applicable to plasma, serum, as well as urine. As TDM, these tests should allow for more effective dosing of the patients and thereby improving treatment effectiveness. The tests are also patient-centric, inviting better compliance and patient participation in personalizing treatment. The simplicity of the assays would allow for field deployment during clinical development for population pharmacokinetics as well as deployment in underdeveloped regions lacking access to central laboratories.   These findings will be presented at the 9th European Congress on Menopause and Andropause, Athens, Greece, March 28-31, 2012.

Abstract 379: Therapeutic Drug Monitoring (TDM) assays for LH and FSH   . V. Trieu, L. Hwang, K. Motamed, C. Hsiao. BIOMIGA DIAGNOSTICS, Fountain Valley, CA.  Presentation Time:  March 28th, 2012, 8:00-18:00. Location: Exhibition Area as Electronically Viewed Posters

About EMA2012:
EMAS 2012 – the 9th inspiring and multi-disciplinary Menopause and Andropause conference- is organised by the European Menopause and Andropause Society (EMAS) and hosted by the Hellenic Society for the Study of Climacterium and Menopause, the congress will explore current problems and the latest advances in the field. No other congress provides as much information about how science is changing the clinical practice of midlife health in both women and men.

About Biomiga Diagnostics
Biomiga Diagnostics’ mission is to transform healthcare by point-of-care tests for Therapeutic Drug Monitoring.  These tests are simple to use and require no specialized equipment or trained personnel.  They are rapid with results within 20 minutes of blood collection.  They are convenient and can be deployed at home, in doctor’s office, in emergency rooms, or in centralized laboratories. Moreover, they are quantitative with linear response range similar to tests performed at centralized laboratories.  These proprietary diagnostic devices deployed at point-of-care are the solution to personalized healthcare, allowing the dosing of the right patient with the right drug at the right dose.

The executives of Biomiga Diagnostics are a group of pharmaceutical veterans who believe that the next revolution in medicine is in point-of-care tests for optimal drug dosing.  With more than a decade of drug development experience each, the leadership team has expertise ranging from basic/applied research, preclinical/clinical development, pharmacokinetics/pharmacodynamics biomarker development, mobile technology, regulatory, legal, marketing and business development. http://www.biomigadiagnostics.com


Contact:
Vuong Trieu PhD
Chief ExecutiveOfficer
vtrieu@biomigadiagnostics.com

or
KourosMotamed PhD
Chief Technology Officer
kmotamed@biomigadiagnostics.com